14
Participants
Start Date
January 28, 2019
Primary Completion Date
March 4, 2022
Study Completion Date
March 4, 2022
Placebo for antibiotic
Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
Vancomycin pretreatment
Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
Nivolumab
Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
Matching Placebo for SER-401
Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
SER-401
Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
Memorial Sloan Kettering Cancer Center, New York
MD Anderson Cancer Center, Houston
Huntsman Cancer Institute, Salt Lake City
The Angeles Clinic and Research Institute, Los Angeles
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey, New Brunswick
Seres Therapeutics, Inc.
INDUSTRY
Parker Institute for Cancer Immunotherapy
OTHER